AI for Science | GTC Live Washington, D.C. Chapter 4

What It Covers

Scientists and technologists explore how AI and quantum computing accelerate discovery across drug development, molecular design, and chip engineering, examining the convergence of classical and quantum systems for scientific breakthroughs.

Key Questions Answered

• •Drug Discovery Timeline: Current drug development takes 13 years from molecular target to FDA approval with 90% failure rate and $2-4 billion cost per drug. AI aims to transform this artisanal process into engineering discipline by 2035.
• •Commercialization Strategy: Quantum technologies follow NVIDIA's staged market approach by targeting areas with immediate quantum advantage like timekeeping and RF sensors before pursuing the crown jewel of quantum computing that surpasses classical systems.
• •Computational Shift Phases: AI infrastructure represents only horizon one of three growth phases. Physical AI for autonomous vehicles and robotics comprises horizon two, while scientific AI for drug and material discovery forms horizon three, each reinforcing previous layers.
• •Logical Qubit Milestone: Quantum advantage requires scaling from today's 12 logical qubits to 100 for material science applications and 1,000 for drug discovery. AI accelerates error correction needed to create these pristine computational qubits.